

LA JOLLA PHARMACEUTICAL CO

Form 8-K

June 10, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 or 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): June 9, 2004

**La Jolla Pharmaceutical Company**

---

(Exact Name of Registrant as Specified in Charter)

Delaware

0-24274

33-0361285

---

(State or Other Jurisdiction  
of Incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

6455 Nancy Ridge Drive, San Diego, California

92121

---

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

N/A

---

(Former Name or Former Address, if Changed Since Last Report)

---

---

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

SIGNATURES

EXHIBIT INDEX

EX-99.1

EX-99.2

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On June 9, 2004, the Company issued a press release announcing that Steven B. Engle, the Company's Chief Executive Officer, would present at the Third Annual Needham Biotechnology Conference on June 17, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On June 10, 2004, the Company issued a press release announcing that the Company would present previously released results from its Phase 2/3 and Phase 3 clinical trials of Riquent® (abetimus sodium) at EULAR's Annual European Congress of Rheumatology on June 9-12, 2004. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) *Exhibits.* The following exhibits are filed with this report on Form 8-K:

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Needham Biotechnology Conference Press Release
99.2	EULAR Annual European Congress of Rheumatology Press Release

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LA JOLLA PHARMACEUTICAL  
COMPANY**

Date: June 10, 2004

By: /s/ Gail A. Sloan  
Gail A. Sloan  
Vice President of Finance and  
Controller

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Needham Biotechnology Conference Press Release
99.2	EULAR Annual European Congress of Rheumatology Press Release